PLK1 and ovarian carcinoma: Our previous work further demonstrated that TP53 mutations alone may not be a reliable marker of sensitivity to WEE1 inhibition and that cyclin E1 overexpression sensitizes ovarian cancer cells to PLK1 and WEE1 inhibition, identifying its role as a predictive biomarker [41].